Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
- Category: Antibodies
- Published on Tuesday, 11 June 2019 10:43
- Hits: 783
- NOBILITY showed that Gazyva helped more patients achieve a complete renal response when added to standard of care
- The Phase II study met both primary and key secondary endpoints
- There are currently no FDA-approved therapies for lupus nephritis
SOUTH SAN FRANCISCO, CA, USA I June 10, 2019 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis. The study met its primary endpoint, showing Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year. In addition, Gazyva met key secondary endpoints showing improved overall renal responses (complete and partial renal response) and serologic markers of disease activity as compared to placebo.
“There are no FDA-approved treatments for lupus nephritis, a potentially life-threatening condition in which patients are at high risk for progressing to end-stage renal disease or death,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We have been investigating a possible treatment for lupus nephritis for more than a decade and have integrated key learnings from that experience in how we study the condition. We are encouraged by the NOBILITY results, which showed a statistically significant difference in achievement of complete renal response, overall renal response, and other measures of disease activity and support the potential for a new treatment option for people living with lupus nephritis.”
Lupus nephritis is a severe and potentially life-threatening manifestation of systemic lupus erythematosus (SLE) resulting from inflammation of the kidneys, with proliferative lupus nephritis being the most severe form and associated with the highest risk of end-stage renal disease and death. 1,2 In addition to meeting the primary endpoint, the study’s key secondary endpoint, defined as achievement of overall renal response (complete or partial renal response) at one year, was also met. No new safety signals were observed with Gazyva in the study at the time of this analysis. The full results from the study will be presented at a future medical meeting.
About the NOBILITY Study
The Phase II, randomized, double-blind, placebo-controlled, multi-center study, NOBILITY (NCT02550652), compares the safety and efficacy of Gazyva, combined with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and corticosteroids, to placebo, combined with MMF or MPA and corticosteroids, in adult patients with ISN/RPS 2003 Class III or IV proliferative lupus nephritis. The study enrolled 126 people who were randomized to receive Gazyva or placebo infusions on Days 1, 15, 168, and 182. The primary endpoint was the proportion of participants who achieved a protocol-defined complete renal response (CRR) at 52 weeks.
About Lupus Nephritis
Lupus nephritis is a severe and potentially life-threatening disorder of the kidneys. Lupus nephritis is a complication of systemic lupus erythematosus (SLE), an autoimmune disease where a person's own immune system attacks healthy cells and organs.1 An estimated 1.5 million Americans are affected by lupus, with approximately 70 percent of cases representing SLE.1,3 Up to 60 percent of people with SLE will develop lupus nephritis, and up to 25 percent of people with the condition develop end-stage renal disease.1,2 Lupus nephritis overwhelmingly impacts women, particularly young women of color. About 90 percent of those diagnosed are women, and African-American, Hispanic, Native American and Asian-American women are two to three times more likely than Caucasian women to get lupus.3,4 Currently, there is no cure for lupus or lupus nephritis.4
Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found only on certain types of B-cells. It is thought to work by attacking targeted cells both directly and together with the body's immune system. In the United States, Gazyva is part of a collaboration between Genentech and Biogen. Combination studies investigating Gazyva with other approved or investigational medicines, including cancer immunotherapies and small molecule inhibitors, are underway across a range of blood cancers.
Gazyva® (obinutuzumab) is a prescription medicine used:
- With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.
- With the chemotherapy drug, bendamustine, followed by Gazyva alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment.
- With chemotherapy, followed by Gazyva alone in those who responded, to treat stage II bulky, III, or IV FL in adults who have not had previous FL treatment.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
1 A. de Zubiria Salgado and C. Herrera-Diaz, Lupus Nephritis: An Overview of Recent Findings. Autoimmune Diseases, vol. 2012, Article ID 849684, 221 pages, 2012. doi:10.1155/2012/849684
2 R. Saxena et al. Lupus Nephritis: Current Update. Arthritis Research & Therapy, 2011, 13:240. doi:10.1186/ar3378
3 Lupus Foundation of America. Lupus Facts and Statistics. https://www.lupus.org/resources/lupus-facts-and-statistics (Last accessed May 6, 2019)
4 Lupus Research Alliance. Lupus Fact Sheet. http://www.lupusresearch.org/wp-content/uploads/2017/09/Lupus-Fact-Sheet.pdf (Last accessed May 6, 2019)